Clinical Documents

To edit the draft, click on the text box below.

×

Draft a comprehensive differential diagnosis for acute substernal chest pain in a 45-year-old male with hypertension and hyperlipidemia, diaphoresis, exertional onset, and normal initial ECG/troponin; include life-threatening causes first, key distinguishing features, and immediate diagnostic next steps.

Draft a detailed differential diagnosis for new-onset unilateral throbbing headache with visual aura and brief monocular vision loss in a 32-year-old female on oral contraceptives; include red-flag symptoms, stroke/TIA considerations, and recommended initial workup.

Draft an assessment and plan for stage-2 hypertension (BP 162/98) in an obese 52-year-old with suspected obstructive sleep apnea; include ASCVD risk estimate, lifestyle prescriptions, first-line pharmacotherapy with drug/dose/targets, baseline labs/monitoring, and 4–6 week follow-up.

Draft an assessment and plan for type 2 diabetes follow-up with A1c 9.2% on metformin 1,000 mg BID and eGFR 65; compare adding a GLP-1 receptor agonist vs an SGLT2 inhibitor, address weight loss goals, hypoglycemia education, vaccinations, and micro/macrovascular screening.

Draft a history and physical for a patient presenting with chest pain, including HPI using OLDCARTS, pertinent ROS, PMH/meds/allergies, FH/SH, focused cardiac/pulmonary exam, initial labs and imaging orders, prioritized differential, HEART score risk stratification, and early management.

Draft a history and physical for a new patient with progressive exertional dyspnea, orthopnea, and bilateral leg edema; include differential (heart failure, COPD, PE, anemia, renal disease), targeted exam maneuvers, and first-line diagnostics and management.

Draft a progress note for COPD follow-up two weeks after an acute exacerbation treated with prednisone and antibiotics; include symptom trajectory, CAT score (if available), inhaler technique/adherence, oxygen needs, spirometry plan, smoking cessation counseling, and return precautions.

Draft a progress note for post-operative day 2 after total knee arthroplasty; include pain control strategy, DVT prophylaxis, PT/OT milestones, wound status, bowel/urinary function, labs/vitals review, complications screening, and discharge readiness.

Draft a discharge summary for community-acquired pneumonia admission; include admission/discharge dates, presenting symptoms, radiology/labs, pathogen if identified, inpatient therapies and response, discharge medications with durations, pending tests, follow-up appointments, and return precautions.

Draft a discharge summary for myocardial infarction managed with PCI and drug-eluting stent placement; include cath findings, complications, inpatient course, discharge medications (DAPT, statin, beta-blocker, ACEi/ARB), cardiac rehab referral, and follow-up plan.

Draft discharge instructions for a patient hospitalized with acute decompensated heart failure; include daily weights, sodium and fluid restriction amounts, medication list with dosing, signs of worsening heart failure, follow-up appointments, and lab monitoring plan.

Draft discharge instructions for an asthma exacerbation; include controller and reliever regimen, steroid taper schedule, spacer technique, trigger avoidance, a written asthma action plan, return precautions, and follow-up timing.

Draft a patient handout on managing high blood pressure in plain language; explain what BP numbers mean, key lifestyle steps (DASH diet, sodium limits, alcohol moderation), home BP monitoring instructions, medication adherence tips, and when to call the doctor.

Draft a patient handout for type 2 diabetes education in plain language; cover A1c goals, the plate method, physical activity targets, self-monitoring of blood glucose, hypoglycemia signs and the 15-15 rule, foot care basics, and a vaccination checklist.

Draft a summary of the latest CDC and WHO guidelines for managing community-acquired pneumonia in adults, including empiric antibiotic choices, duration of therapy, and follow-up recommendations.

Draft a plain-language overview of the ADA and AACE guidelines for diabetes management, focusing on A1c goals, weight management, and the use of GLP-1 receptor agonists and SGLT2 inhibitors.

Draft a summary of the 2024 USPSTF breast cancer screening recommendations, including updated screening intervals, risk-based approaches, and the role of MRI for high-risk patients.

Draft a concise summary of NCCN guidelines for melanoma management, including staging, surgical margins, adjuvant therapy, and checkpoint inhibitor recommendations.

Draft treatment alternatives for community-acquired MRSA skin infections in patients allergic to sulfa drugs; include oral and IV options, dosing, and duration.

Draft treatment alternatives for patients with type 2 diabetes who are unable to tolerate GLP-1 receptor agonists due to nausea; include medication substitutions and lifestyle recommendations.

Draft a summary of options for treating refractory depression, comparing ketamine infusions, transcranial magnetic stimulation (TMS), and electroconvulsive therapy (ECT).

Draft treatment options for advanced prostate cancer, including hormonal therapy, radiopharmaceuticals, and novel androgen receptor pathway inhibitors.

Draft a summary of recent research on mRNA vaccine technology beyond COVID-19, including applications in oncology and autoimmune disease prevention.

Draft an easy-to-understand overview of long COVID research, summarizing major symptoms, hypothesized mechanisms, and emerging treatment approaches.

Draft a summary of current research on Alzheimer’s disease biomarkers, including amyloid and tau imaging, and discuss how they influence diagnosis and trial design.

Draft an explanation of the interaction between warfarin and antibiotics such as ciprofloxacin or TMP-SMX, including INR effects and management recommendations.

Draft a summary evaluating drug interactions for patients taking Paxlovid and common cardiovascular drugs; include mechanism and recommended dose adjustments.

Draft a summary of the common and serious side effects of semaglutide, including GI intolerance, gallbladder disease, and thyroid-related warnings.

Draft an overview of potential side effects associated with long-term corticosteroid use, including osteoporosis, glucose intolerance, and adrenal suppression.

Draft a summary of essential lab tests to order in suspected acute pancreatitis, including amylase, lipase, liver enzymes, and metabolic panels, with interpretation guidance.

Draft laboratory workup recommendations for suspected hypothyroidism, including TSH, free T4, thyroid antibodies, and when to consider secondary causes.

Draft an explanation of which labs should be monitored in patients receiving methotrexate therapy, including CBC, LFTs, renal function, and frequency of monitoring.

why choose us

Edit Geo

×

300×250 Ad Slot

Research Article: A study on the correlation between systemic inflammatory markers in the local tumor immune microenvironment and Porphyromonas gingivalis infection status in patients with oral squamous cell carcinoma

Date Published: 2026-07-29

Abstract:
This study investigates the relationship between Porphyromonas gingivalis ( P. gingivalis ) infection status and preoperative levels of inflammatory markers in peripheral blood as well as the tumor immune microenvironment (TIME) in patients with oral squamous cell carcinoma (OSCC). This retrospective study enrolled 201 patients with oral squamous cell carcinoma (OSCC) and collected their relevant clinical data, preoperative peripheral blood samples, and histopathological sections. Immunohistochemical analysis was performed to assess P. gingivalis expression levels in the patients’ tissue samples, and the patients were divided into high-expression and low-expression groups. First, we analyzed the relationships between clinical indicators—such as tumor stage and pathological grade—and P. gingivalis expression levels. Additionally, systemic inflammation markers, including the systemic immune–inflammation index (SII), the neutrophil–lymphocyte ratio (NLR), the platelet–lymphocyte ratio (PLR), and the systemic inflammatory response index (SIRI), were calculated on the basis of peripheral blood test results; we analyzed the correlations of these variables with clinical indicators and P. gingivalis expression levels. At the same time, immunohistochemical analysis was performed on OSCC tissue samples to assess the abundance of CD4+ T cells and the expression of chemokine ligand 20 (CCL20), chemokine receptor 6 (CCR6), interleukin 10 (IL-10), FOXP3, and LAG-3 in OSCC tissue samples to assess the relationship between P. gingivalis expression levels and systemic inflammatory markers in peripheral blood as well as the local immunosuppressive microenvironment. Patients with higher P. gingivalis expression levels in tumor tissue had lower tumor differentiation ( P < 0.001) and shorter survival times ( P < 0.001). Two systemic inflammatory markers—the SII and SIRI—were associated with tumor differentiation (SII: P = 0.020; SIRI: P = 0.004), while the SII, NLR, PLR, and SIRI were associated with the T stage (SII: P < 0.001; NLR: P = 0.003; PLR: P = 0.017; SIRI: P = 0.003); the SII and PLR were associated with the N stage (SII: P = 0.002; PLR: P = 0.046). The NLR and SIRI were associated with P. gingivalis expression levels (NLR: P = 0.026; SIRI: P = 0.021). Multivariate logistic regression analysis revealed that pT stage is an independent risk factor for high expression of P. gingivalis , exhibiting a dose-response relationship (pT2: OR = 5.83, pT3: OR = 11.69, pT4: OR = 43.66; all P < 0.01); poorly differentiated tumors (OR = 11.02) and lip cancer (OR = 0.27) were also independent risk factors ( P < 0.05). Immunohistochemical results revealed that OSCC patients with higher P. gingivalis levels had significantly higher positive expression of CD4, FOXP3, LAG3, CCR6, CCL20, and IL-10 (CD4, FOXP3, LAG3, CCR6, IL-10: P < 0.0001; CCL20: P = 0.0006). Four systemic inflammation markers—the SII, NLR, PLR, and SIRI—were associated with the expression levels of FOXP3, CCR6, CCL20, and IL-10 in OSCC tumor tissues ( P < 0.05); among these markers, the SII and PLR were significantly associated with LAG3 expression levels ( P < 0.05). Furthermore, only SIRI values were associated with CD4 expression levels ( P < 0.05). P. gingivalis alters the local immune status by modulating key immune molecules—CD4, FOXP3, CCL20, CCR6, LAG-3, and IL-10—in the OSCC tumor microenvironment. These local changes are significantly associated with systemic inflammation levels, indicating a close interaction between the local immune microenvironment and systemic inflammatory responses, both of which contribute to the development and progression of OSCC.

Introduction:
Oral cancer is a common malignant tumor of the head and neck. Globally, it ranks sixth among the most common types of cancer, with over 90% of cases presenting as oral squamous cell carcinoma (OSCC) ( 1 ). The International Classification of Diseases defines oral cancer as cancer of the oral cavity and pharynx, including cancers of the lips, tongue, cheeks, gums, floor of the mouth, oropharynx, nasopharynx, and hypopharynx ( 2 ). According to the latest data from the GLOBOCAN database, in 2022, lip and oral…

Read more

300×250 Ad Slot

×
Chat & Ask Questions Career Openings Medical Doctors Check on Drug
Interactions Latest Health News
by WebHealthNetwork Get CME Credits Latest Clinical Trials Latest Research Articles Clinical Documents Update Profile

News

Chat

HCP Tools

Careers

Update Profile